{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Autologous Skin Cell Suspension with Split-Thickness Skin Grafting for Nonthermal Skin Defects"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "randomised 1:1 to receive either standard meshed STSG (control) or ASCS+STSG. Randomisation was performed using sealed envelopes, and outcome assessors were blinded. The primary outcomes were noninferiority of ASCS+STSG for complete closure by 8 weeks and superiority in reducing donor skin area. Sample size was calculated to provide \u226580% power for both primary endpoints."
      },
      "Participants": {
        "score": 2,
        "evidence": "65 patients aged 5 years or older with acute full-thickness nonthermal skin defects were randomised 1:1 to receive either standard meshed STSG (control) or ASCS+STSG."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to receive either standard meshed STSG (control) or ASCS+STSG."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial evaluated the efficacy of autologous skin cell suspension (ASCS) combined with split-thickness skin grafting (STSG) in reducing donor skin requirements for full-thickness nonthermal skin defects."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcomes were noninferiority of ASCS+STSG for complete closure by 8 weeks and superiority in reducing donor skin area."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using sealed envelopes, and outcome assessors were blinded."
      },
      "Blinding": {
        "score": 1,
        "evidence": "outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "65 patients aged 5 years or older with acute full-thickness nonthermal skin defects were randomised 1:1"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 65 randomised patients, 52 were analysed per protocol."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "At 8 weeks, complete closure was achieved in 65% of ASCS+STSG areas versus 58% of control areas (p = 0.005), confirming noninferiority. ASCS+STSG required 27.4% less donor skin (p < 0.001), establishing superiority."
      },
      "Harms": {
        "score": 1,
        "evidence": "Safety profiles were comparable, with no serious ASCS device-related events."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT04091672."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}